Joseph Brewer, MD
Infectious Disease · Kansas City, MONPI 1417981846
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 380 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 380 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1K
- Viiv Healthcare Company$966
- Gilead$875
- Johnson & Johnson$670
- Melinta Therapeutics, LLC$558
- AbbVie$472
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$1853%
- Food & beverage$6,16493%
- Education$2894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 63 | $1,155 |
| Viiv Healthcare Company | 60 | $966 |
| Gilead | 58 | $875 |
| Johnson & Johnson | 38 | $670 |
| Melinta Therapeutics, LLC | 36 | $558 |
| AbbVie(2 entities) | 27 | $472 |
| Insmed, Inc. | 22 | $416 |
| La Jolla Pharmaceutical Company | 17 | $282 |
| Napo Pharmaceuticals Inc | 14 | $280 |
| Astellas Pharma US Inc | 3 | $139 |
| Mayne Pharma Commercial LLC | 6 | $136 |
| Shionogi Inc | 4 | $108 |
| Shire North American Group Inc | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Theratechnologies Inc. | 5 | $82 |
| Mylan Institutional Inc. | 2 | $47 |
| Vyera Pharmaceuticals, LLC | 2 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $35 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Janssen Products, LP | 1 | $29 |
| Octapharma USA, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $20 |
| Pfizer | 1 | $17 |
| Abiomed | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| ADMA Biomanufacturing LLC | 1 | $13 |
How this compares
$6,639 in reported general payments places this provider in the 85th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RukobiaFostemsavir Tromethamine | 23 | $235,374 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 45 | $166,539 |
| TivicayDolutegravir Sodium | 42 | $144,896 |
| DescovyEmtricitabine/Tenofov Alafenam | 24 | $68,629 |
| PrezcobixDarunavir/Cobicistat | 21 | $61,893 |
| JulucaDolutegravir/Rilpivirine | 14 | $50,183 |
| PifeltroDoravirine | 22 | $43,023 |
| MytesiCrofelemer | 11 | $38,619 |
| Daptomycin | 27 | $34,472 |
| EdurantRilpivirine Hcl | 14 | $20,888 |
| Maraviroc | 12 | $14,821 |
| Cefpodoxime Proxetil | 56 | $12,065 |
| ErtapenemErtapenem Sodium | 28 | $7,410 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 66 | $6,993 |
| CefuroximeCefuroxime Axetil | 81 | $5,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyRukobia, Triumeq, Tivicay, Juluca | $966 | $596,992124 claims |
| GileadDescovy | $875 | $68,62924 claims |
| Johnson & JohnsonPrezcobix | $670 | $61,89321 claims |
| MerckPifeltro | $1,155 | $43,02322 claims |
| Napo Pharmaceuticals IncMytesi | $280 | $38,61911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Kansas City
- Paul JostKansas City$6K
- Muna AbuerreishKansas City$3K
- Arundhati DesaiKansas City$3K
- David McKinseyKansas City$796
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.